Press Releases

August 13, 2020
Protagonist Appoints Sarah O'Dowd to Board of Directors Read More
August 6, 2020
Protagonist Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update Read More
June 17, 2020
Hepcidin Mimetic PTG-300 Receives U.S. FDA Orphan Drug Designation for the Treatment of Polycythemia Vera Read More
June 16, 2020
Protagonist Therapeutics to Participate in the BMO Prescriptions for Success Healthcare Conference Read More
June 4, 2020
Protagonist Therapeutics to Present at the 25th European Hematology Association (EHA) Annual Congress Read More
May 28, 2020
Protagonist Therapeutics to Present at Two Upcoming Healthcare Investor Conferences Read More
May 12, 2020
Protagonist Therapeutics, Inc. Announces Upsizing and Pricing of Underwritten Public Offering of 7,000,000 Shares of Common Stock Read More
May 11, 2020
Protagonist Therapeutics, Inc. Announces Proposed Underwritten Public Offering of Common Stock Read More
May 7, 2020
Protagonist Therapeutics Reports First Quarter Financial Results and Provides Corporate Update Read More
May 7, 2020
Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera Read More
May 4, 2020
Protagonist Therapeutics to Announce First Quarter 2020 Financial Results and Provide Corporate and R&D Update Read More
April 15, 2020
Protagonist Therapeutics Reports Granting of Inducement Award Read More
March 10, 2020
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results Read More
March 2, 2020
Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results Read More
February 19, 2020
Protagonist Therapeutics to Present at the SVB Leerink 9th Annual Global Healthcare Conference in New York Read More
February 7, 2020
Protagonist Therapeutics to Present Preclinical Results on PN-943 at the 15th Congress of European Crohn's and Colitis Organization (ECCO) Read More
January 7, 2020
Protagonist Therapeutics Achieves Milestone in Janssen Biotech, Inc., Collaboration Read More
January 6, 2020
Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis Read More
December 3, 2019
Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia Read More
November 13, 2019
Protagonist Therapeutics to Present at Two Upcoming Healthcare Investor Conferences Read More